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382Outcomes after endovascular abdominal aortic
aneurysm repair are equivalent between genders
despite anatomic differences in women
Luc Dubois, MD, MSc, Teresa V. Novick, RN, Jeremy R. Harris, MD, Guy DeRose, MD, and
Thomas L. Forbes, MD, London, Ontario, Canada
Objective: Prior work conﬁrms gender-speciﬁc anatomic differences in patients undergoing endovascular aneurysm repair,
but the clinical implications remain ill deﬁned. The purpose of this study was to compare gender-speciﬁc early outcomes
after endovascular aneurysm repair using a large international registry.
Methods: Over the 2-year period ending in 2011, 1,262 patients (131 women, 10.4%; 1,131 men, 89.6%) with infrarenal
aneurysms treated with the Endurant stent graft were prospectively enrolled in the ENGAGE registry and followed
clinically and radiographically.
Results: Women were older (75.5 ± 7.0 vs 72.8 ± 8.1; P [ .0003) and had smaller aneurysms (57.8 ± 9.5 vs
60.6 ± 11.9 mm; P [ .01). Women’s infrarenal aortic necks were of narrower diameter (21.8 ± 3.4 vs 24.0 ± 3.5 mm;
P < .0001), shorter length (24.3 ± 11.8 vs 27.3 ± 12.4 mm; P [ .009), and greater angulation (37.7 ± 26.2 vs
29.4 ± 23.3; P[ .0002). More women had an infrarenal neck angle >60 (19.2% vs 9.1%; P[ .001). Technical success
was achieved in equal numbers of women and men (97.7% vs 99.2%; P[ .10). On completion angiography, the incidence
of any endoleak (21.5% vs 15.4%; P[ .08) and type I endoleak (1.5% vs 1.1%; P[ .60) did not differ between genders.
At the 1-month follow-up, there were no differences between women and men with respect to endograft occlusion (2.5%
vs 1.9%; P [ .70), and differences observed in any endoleak (17.2% vs 11.4%; P [ .08) and type I endoleaks (3.3% vs
1.2%; P[ .08) did not reach statistical signiﬁcance. Freedom from major adverse events was similar for women and men
at 30 days (98.5% vs 95.8%; P[ .23) and 1 year (85% vs 89.8%; P[ .40). Survival at 30 days (100% vs 98.6%) and 1 year
(92.5% vs 91.6%; P [ .99) was similar for women and men.
Conclusions: This large multinational registry conﬁrms the previously observed prevalence of suboptimal neck anatomy in
women. Even though women have shorter and more angulated infrarenal necks, their technical outcomes at 30 days and
clinical outcomes at 1 year were similar to those of men. Much longer follow-up is necessary to determine whether these
outcomes proved durable. (J Vasc Surg 2013;57:382-9.)It has long been suggested that women with abdom-
inal aortic aneurysms (AAAs) fare worse than their male
counterparts. Women tend to have a higher risk of rupture
and a poorer outcome following rupture.1 Some have
advocated a smaller-diameter threshold for repair in
women because of the difference in proportional dilatation
of AAAs of equal size in women and men.2 Along with
poorer outcomes after ruptured aneurysms, women have
recently been observed to suffer a threefold increase in peri-
operative mortality following elective endovascular repair
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://dx.doi.org/10.1016/j.jvs.2012.09.075Several explanations have been suggested for these
poorer outcomes after an EVAR. First, in many series
describing elective AAA repair, women tend to be older
and have more frequent atherosclerotic risk factors than
men.1 In addition, anatomic differences between the sexes,
including more frequent adverse infrarenal neck and iliac
artery anatomy, have resulted in higher rates of procedural
complications and reinterventions in women after an
EVAR.3 These anatomic challenges, and their associated
poorer outcomes, suggest the need for advances in device
design to more fully meet the speciﬁc female aneurysm
anatomy and physiology.
The Endurant stent graft system (Medtronic, Santa
Rosa, Calif) was entered into clinical trials in Europe in
2007, and theU.S. regulatory trial completed its enrollment
in 2009. Speciﬁc features and modiﬁcations have been re-
ported elsewhere and include a lower-proﬁle delivery
system, more ﬂexibility, and active transrenal ﬁxation.4-6
Brieﬂy, the Endurant stent graft system is designed for
infrarenal aneurysms with proximal neck diameters of
19 to 32 mm, proximal neck lengths $10 mm with #60
infrarenal and #45 suprarenal angulations, iliac diameters
of 8 to 25 mm, and distal ﬁxation lengths $15 mm. Since
then, more than 1200 patients from 79 sites in Europe,
Asia–Paciﬁc, South Africa, the Middle East, Latin America,
Table I. Baseline characteristics
Characteristic Men Women P value
Age (years) 72.8 6 8.1a 75.5 6 7.0 <.001
Primary indication for implant
Aneurysm diameter
$1.5  normal infrarenal aorta 3.2% (36/1131)b 4.6% (6/131) .44
4-5 cm ($0.5-cm increase in last 6 months) 5.8% (66/1131) 9.9% (13/131) .07
>5 cm 88.5% (1001/1131) 84.7% (111/131) .21
Other 2.5% (28/1131) 0.8% (1/131) .22
Baseline symptoms
None 84.8% (959/1131) 76.3% (100/131) .01
Abdominal pain 10.1% (114/1131) 16.0% (21/131) .04
Back pain 4.9% (55/1131) 7.6% (10/131) .17
Other 2.6% (29/1131) 1.5% (2/131) .77
Tobacco use 50.0% (551/1101) 43.1% (56/130) .13
Hypertension 75.0% (836/1114) 78.6% (103/131) .37
Hyperlipidemia 59.9% (636/1062) 65.1% (82/126) .26
Diabetes 18.7% (208/1113) 21.4% (28/131) .46
Cancer 20.3% (225/1110) 22.1% (29/131) .62
Cardiac disease 54.4% (615/1130) 45.0% (59/131) .04
Myocardial infarction 27.3% (295/1080) 17.7% (23/130) .02
Arrhythmia 16.1% (178/1105) 15.5% (20/129) .86
Angina 16.0% (176/1103) 12.2% (16/131) .26
Congestive heart failure 5.6% (62/1100) 7.0% (9/129) .54
Coronary artery disease 36.2% (394/1089) 21.7% (28/129) .001
Cardiac revascularization (including CABG or PTCA) 28.8% (321/1114) 12.3% (16/130) <.001
Valvular heart disease 6.2% (68/1105) 6.1% (8/131) .98
Pulmonary disease 24.9% (277/1112) 26.4% (34/129) .72
Renal insufﬁciency 15.4% (172/1120) 14.5% (19/131) .80
Carotid artery disease 10.7% (101/944) 11.8% (13/110) .72
Cerebrovascular/neurological disease 12.7% (143/1130) 13.0% (17/131) .92
Transient ischemic attack 4.6% (52/1119) 6.9% (9/130) .25
Cerebral vascular accident 5.6% (63/1125) 3.1% (4/130) .23
Paraplegia 0.2% (2/1124) 0.8% (1/131) .19
Paraparesis 0.9% (10/1125) 0.0% (0/131) .28
Vascular disease 31.1% (351/1130) 29.8% (39/131) .76
Previous abdominal aortic aneurysm 1.8% (20/1124) 0.0% (0/131) .12
Any thoracic aneurysm 1.8% (19/1082) 3.2% (4/125) .26
Peripheral vascular disease 19.0% (212/1114) 13.1% (17/130) .10
Thromboembolic event 3.3% (36/1107) 3.9% (5/129) .71
Liver disease 2.4% (27/1130) 1.5% (2/131) .53
Alcoholism 3.5% (39/1099) 0.8% (1/129) .12
Family history of aneurysms 6.1% (69/1130) 10.7% (14/131) .04
ASA classiﬁcation
Class I 6.5% (73/1130) 3.1% (4/131) .12
Class II 41.6% (470/1130) 43.5% (57/131) .67
Class III 42.0% (475/1130) 36.6% (48/131) .24
Class IV 9.9% (112/1130) 16.8% (22/131) .02
SVS/ISVS risk level
SVS 0 0.1% (1/1088) 0.0% (0/129) .73
SVS 1 14.2% (155/1088) 8.5% (11/129) .07
SVS 2 51.5% (560/1088) 47.3% (61/129) .37
SVS 3 34.2% (372/1088) 44.2% (57/129) .03
ASA, American Society of Anesthesiologists; CABG, coronary artery bypass graft; ISVS, International Society for Vascular Surgery; PTCA, percutaneous
transluminal coronary angioplasty; SVS, Society for Vascular Surgery.
aMean 6 standard deviation.
b% (m/n).
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ant graft have been placed in the ENGAGE Registry
(Endurant Stent Graft Natural Selection Global Postmarket
Registry). The purpose of the present study was to compare
anatomic and physiologic characteristics and early technical
and clinical outcomes between men and women.METHODS
Over a recent 2-year period ending in April 2011,
patients treated with the Endurant stent graft for nonrup-
tured AAAs were enrolled in the ENGAGE Registry, which
is a multicenter, multinational, nonrandomized, single-arm
prospective study of the Endurant stent graft device.
Table II. Anatomic characteristics
Characteristic Men (n ¼ 1131) Women (n ¼ 131) P value
Size of aneurysm (mm) 60.6 6 11.9a 57.8 6 9.5 .01
Infrarenal proximal aortic neck diameter (mm) 24.0 6 3.5 21.8 6 3.4 <.001
Length of aortic neck (mm) 27.3 6 12.4 24.3 6 11.8 <.001
Diameter of right common iliac artery (mm) 14.3 6 3.5 12.9 6 3.5 <.001
Diameter of left common iliac artery (mm) 13.9 6 3.6 12.5 6 2.9 <.001
Infrarenal aortic neck angle () 29.4 6 23.3 37.7 6 26.2 <.001
Infrarenal neck angle greater than 60 (%, m/n) 9.1% (100/1095)b 19.2% (25/130) .001
aMean 6 standard deviation.
b% (m/n).
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to-treat basis. There were 79 participating centers in 30
countries (Appendix).
Details regarding the ENGAGE Registry have been
previously published.7 In brief, patient inclusion criteria
included age $18 years and indication for elective repair
of an AAA with an endovascular stent graft in accordance
with guidelines on endovascular aneurysm repair.8 Patients
were excluded if they were deemed to have a high proba-
bility of nonadherence to follow-up or if they were partici-
pating in another trial that could confound the study
results. Data were collected by the participating institu-
tions on electronic data forms and submitted to a central
registry.
We compared the results obtained in men (n ¼ 1131;
89.6%) with those obtained in women (n ¼ 131; 10.4%).
Baseline data including comorbidities (hypertension, hyper-
lipidemia, cardiac disease, diabetes, tobacco use, cancer,
carotid disease, and renal insufﬁciency); aneurysm anatomy
(aneurysm diameter, neck length, neck diameter, iliac artery
diameters, and infrarenal neck angle); American Society
of Anesthesiologists classiﬁcation; and Society for Vascular
Surgery/International Society for Vascular Surgery scores
were collected. Perioperative outcomes included technical
success (successful delivery and deployment of stent graft
in the absence of stent graft malfunction, kinking/twisting,
or fracture), freedom from intraoperative death or type I/
III endoleak, conversion to open surgery, and the need for
secondary endovascular procedures. Outcomes assessed
at 30 days postprocedure included all-cause mortality,
freedom from major adverse events, technical failure (stent
fracture, kinking, loss of structural integrity), stent graft
occlusion, and presence of endoleak. One-year outcomes
were limited to all-cause mortality and freedom from major
adverse events for the 493 patients who had reached this
milestone.
Statistical analysis. Categorical data are expressed as
proportions and percentages, whereas continuous data are
expressed as means 6 standard deviations. Continuous vari-
ableswere analyzedusing Student’s t-test,whereas categorical
variables were compared using the c2 test or Fisher exact test
where appropriate. All tests were two-tailed with signiﬁcance
set atP value<.05. All statistical analysis was carried out using
SPSS 20.0 software (SPSS Inc, Chicago, Ill).RESULTS
Baseline characteristics. Over the study period,
1262 patients were enrolled in the ENGAGE Registry, the
majority being male (n ¼ 1131, 89.6%). Baseline compari-
sons between men and women are outlined in Table I.
Womenwhowere older (75.56 7.0 vs 72.86 8.1 years;P<
.001) were more likely to be symptomatic (23.7% vs 15.2%;
P¼ .01), less likely to have coronary artery disease (45.0% vs
54.4%; P ¼ .04), and more likely to have a family history of
aneurysms (10.7 vs 6.1%; P ¼ .04) than men. Other
comorbidities and baseline characteristics were similar for
men and women.
A total of 337 patients were treated at participating
centers outside the ENGAGE Registry. Most common
reasons for exclusion were difﬁculties with consent, high
likelihood of study nonadherence, treatment with another
device, and urgent presentation.
Anatomic characteristics. Anatomic details are sum-
marized in Table II. Women had smaller-diameter aneurysms
(57.8 6 9.5 mm vs 60.6 6 11.9 mm; P ¼ .01), smaller-
diameter aortic necks (21.86 3.4mm vs 24.06 3.5mm; P<
.001), shorter aortic necks (24.3 6 11.8 mm vs 27.3 6 12.4
mm; P< .001), smaller-diameter iliac arteries (12.96 3.5 and
12.5 6 2.9 vs 14.3 6 3.5 and 13.9 6 3.6 mm; P < .001),
and greater infrarenal aortic neck angles (37.7 6 26.2 vs
29.46 23.3; P< .001) when compared with men.
Procedure data. Most procedural details were similar
between men and women (Table III). Men did have
a higher proportion of iliac limbs placed beyond the iliac
bifurcation (right: 9.4% vs 3.8%; P ¼ .03; left: 8.9% vs 3.1%;
P ¼ .02) and had higher rates of coil embolization of an
internal iliac artery during the implant procedure (5.6% vs
0.8%; P ¼ .02) than women. Length of hospital stay,
length of postprocedure stay, and length of intensive care
unit stay were similar for the two groups.
Outcomes. Despite differences in anatomy, early
outcomes were similar between the two groups, with the
outcomes summarized in Table IV. No difference was
observed in technical success (99.2% vs 97.7%; P ¼ .1),
freedom from intraoperative death (100% both groups), or
freedom from type I/III endoleak (98.7% vs 97.7%;
P ¼ .38). Presence of any uncorrected endoleak (15.4% vs
21.5%; P ¼ .08) or type I endoleak (1.1% vs 1.5%; P ¼ .65)
Table III. Procedural data
Characteristic Men Women P value
Preimplant adjunctive procedure performed 8.0% (91/1131)a 3.8% (5/131) .08
Coil embolization of internal iliac artery 4.5% (51/1131) 2.3% (3/131) .24
Coil embolization of inferior mesenteric artery 1.2% (14/1131) 0.0% (0/131) .20
Other preimplant adjunctive procedure 2.5% (28/1131) 1.5% (2/131) .50
Duration of implant procedure (minutes) 99.8 6 44.5b 97.2 6 49.1 .57
Type of anesthesia used
General 62.5% (706/1130) 60.3% (79/131) .63
Spinal 20.4% (231/1130) 26.7% (35/131) .10
Epidural 8.7% (98/1130) 3.1% (4/131) .03
Local 13.5% (152/1130) 11.5% (15/131) .52
Estimated blood loss during procedure (cc) 208.4 6 224.6 208.0 6 178.5 .98
Volume of contrast (cc) 131.9 6 70.6 120.7 6 70.1 .09
Total ﬂuoroscopic time (minutes) 20.6 6 12.5 19.4 6 11.2 .27
Placement of Endurant stent graft
Proximal end of the device was placed, % (m/n)
With suprarenal stents crossing both renal arteries 76.3% (863/1131) 70.2% (92/131) .13
With suprarenal stents crossing one renal artery 5.9% (67/1131) 6.9% (9/131) .67
Below both renal arteries 17.0% (192/1131) 22.1% (29/131) .14
Not applicable 0.8% (9/1131) 0.8% (1/131) .97
Limb extension deployed distal to right internal iliac origin 9.4% (106/1131) 3.8% (5/131) .03
Limb extension deployed distal to left internal iliac origin 8.9% (101/1131) 3.1% (4/131) .02
Associated procedures performed during implant procedure
Coil embolization of internal iliac artery 5.6% (63/1131) 0.8% (1/131) .02
Coil embolization of inferior mesenteric artery 0.6% (7/1131) 0.0% (0/131) .37
Other 8.8% (99/1131) 8.4% (11/131) .89
None 85.9% (972/1131) 90.8% (119/131) .12
Hospital stay (days) 6.40 6 6.10 7.78 6 9.72 .11
Postprocedure stay (days) 4.73 6 4.97 5.63 6 5.87 .09
Duration of ICU stay (hours) 10.4 6 44.6 7.6 6 18.3 .18
ICU, Intensive care unit.
a% (m/n).
bMean 6 standard deviation.
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between men and women. Similarly, at 30 days, no differ-
ences were found in the rate of endoleaks (11.4% vs 17.2%;
P¼ .08), endograft occlusions (1.9% vs 2.5%;P¼ .70), type I
endoleaks (1.2% vs 3.3%; P ¼ .08), and the need for
secondary endovascular procedures (1.5% vs 0.8%; P ¼ .50)
between men and women. Importantly, half of the men
(6 of 12) and half of the women (2 of 4) who had type I
endoleaks at 30 days had anatomy outside Endurant’s
instructions for use. The two genders were similar with
respect to freedom from major adverse events at 30 days
(98.5% vs 95.8; P¼ .23) and 1 year (85% vs 89.8%; P¼ .40;
Fig 1) and survival at 30 days (100% vs 98.6%) and 1 year
(92.5% vs 91.6%; P¼ .99; Fig 2). Several features, including
hospital stay and intensive care unit utilization (Table III),
represent the multinational aspect of the registry and the
varying practice patterns employed in these countries.
DISCUSSION
This study shows that despite clear anatomic differ-
ences between men and women, early results using the
Endurant stent graft are equivalent. No differences were
observed in the rate of technical success, intraoperative
endoleak, or need for secondary procedures. Similar results
were obtained at 30 days, with no difference in freedom
from major adverse events and type I/III endoleaks.Some caution is necessary, however, because, although
not statistically signiﬁcant, there was a trend toward more
frequent endoleaks and type I endoleaks in women at
30 days. Long-term follow-up is necessary to determine
whether these repairs remain durable.
Signiﬁcant differences in aortic anatomy between
genders have been described, differences that generally
make endovascular repair less anatomically suitable in
women. Women are known to have smaller iliac arteries,9-11
shorter and more angulated infrarenal aortic necks,11-14 and
aneurysms that more frequently involve the juxtarenal
aorta.15 These differences make women less likely than
men to undergo an EVAR.11,16 Findings for patients in
the ENGAGE Registry were similar, with women having
shorter, more angulated aortic necks and smaller iliac
arteries. These anatomic differences are thought to nega-
tively inﬂuence the results obtained with EVAR. Smaller
iliac arteries can translate into a higher incidence of access
complications.14 Mehta et al, in a study including
636 women, identiﬁed a higher rate of acute leg ischemia
after an EVAR in women than in men (3.5% vs 0.6%).3
Similarly, Ouriel et al identiﬁed a higher rate of limb occlu-
sion at 24 months among women being treated with EVAR
(11% vs 3.3%).17 Wolf et al also described a higher rate of
intraoperative complications among women undergoing
EVAR, related primarily to access issues and a higher rate
Table IV. Outcomes
Outcome Men Women P value
Immediately after surgery
Technical success 99.2% (1122/1131)a 97.7% (128/131) .10
Freedom from intraoperative death 100.0% (1131/1131) 100.0% (131/131) NA
Freedom from type I/III endoleak 98.7% (1111/1126) 97.7% (127/130) .38
Stent graft kinking 1.2% (13/1123) 0.0% (0/130) .38
Endoleak 15.4% (173/1126) 21.5% (28/130) .08
Type I 1.1% (12/1126) 1.5% (2/130) .60
Type II 12.0% (135/1126) 16.2% (21/130) .21
Type III 0.3% (3/1126) 0.8% (1/130) .35
Type IV 1.9% (21/1126) 0.8% (1/130) .72
Undetermined 0.5% (6/1126) 2.3% (3/130) .06
Conversion to open surgery 0.2% (2/1131) 0.0% (0/131) 1.00
Abdominal aortic aneursym rupture 0.0% (0/1131) 0.0% (0/131) 1.00
Secondary endovascular procedure 0.1% (1/1131) 0.0% (0/131) 1.00
Secondary endovascular procedure to correct type I/III endoleak 0.0% (0/1131) 0.0% (0/131) NA
30 days after surgery
Freedom from major adverse events 95.8% (1084/1131) 98.5% (129/131) .23
All-cause mortality 1.4% (16/1131) 0.0% (0/131) .40
Bowel ischemia 0.2% (2/1131) 0.8% (1/131) .28
Myocardial infarction 1.1% (13/1131) 0.8% (1/131) 1.00
Paraplegia 0.0% (0/1131) 0.0% (0/131) NA
Renal failure 0.4% (4/1131) 0.0% (0/131) 1.00
Respiratory failure 0.0% (0/1131) 0.0% (0/131) NA
Stroke 0.2% (2/1131) 0.0% (0/131) 1.00
Stent graft kinking 1.8% (19/1029) 0.8% (1/122) .71
Stent graft occlusion 1.9% (20/1029) 2.5% (3/122) .70
Endoleak 11.4% (117/1029) 17.2% (21/122) .08
Type I 1.2% (12/1029) 3.3% (4/122) .08
Type II 9.5% (98/1029) 13.1% (16/122) .21
Type III 0.2% (2/1029) 0.0% (0/122) 1.00
Type IV 0.1% (1/1029) 0.0% (0/122) 1.00
Undetermined 0.6% (6/1029) 0.8% (1/122) .55
Freedom from type I/III endoleak 98.7% (1013/1029) 96.7% (118/122) .10
Conversion to open surgery 0.1% (1/1131) 0.0% (0/131) NA
Aneurysm rupture 0.0% (0/1131) 0.0% (0/131) NA
Secondary endovascular procedure 1.5% (17/1131) 0.8% (1/131) .50
Secondary endovascular procedure to correct type I/III endoleak 0.3% (3/1131) 0.8% (1/131) .36
NA, Not applicable.
a% (m/n).
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though women have smaller iliac arteries, no differences in
early endograft occlusion or access-related complications
were found among the ENGAGE cohort. The Endurant
graft may be better suited to challenging aortoiliac
anatomy18 and may better accommodate smaller female
access vessels when compared with previous devices.
However, the effect of increasing operator experience and
improved imaging techniques cannot be discounted.
Despite shorter, more angulated aortic necks, women
had similar rates of endoleak on completion angiography
and had equivalent rates of immediate and 30-day freedom
from type I/III endoleaks when compared with men.
These differences in aortic neck anatomy are thought to
contribute to reports of inferior endovascular outcomes
in women. In the EUROSTAR Registry, endoleaks were
almost twice as likely to develop in women as compared
with men.19 Similarly, Mehta et al found that women
needed twice as many secondary procedures to correct
intraoperative type I endoleaks.3 Other authors have found
no difference in endoleaks or secondary proceduresbetween men and women.13,17 We failed to identify any
differences in endoleaks, need for secondary endovascular
procedures, and rate of technical success between men
and women. Although there was no statistical difference,
we did observe a trend toward more frequent type I endo-
leaks in women than in men at 30 days (3.3% vs 1.2%;
P ¼ .08). Long-term follow-up is necessary to determine
the clinical signiﬁcance of this observation and will be
forthcoming with further registry information.
Although some of the anatomic differences between
men and women have made EVAR more challenging,
other differences may translate into better long-term
outcomes. Women have been shown to have less dilated
iliac arteries than men,12,14 a ﬁnding that may translate
into more durable endovascular repair.20 Our study identi-
ﬁed a reduced need for embolization of internal iliac
arteries and placement of iliac limbs beyond the iliac bifur-
cation in women, indicating that fewer women needed to
have procedural modiﬁcations to treat concomitant iliac
artery aneurysms. These anatomic differences may be
related to differences in the aortic wall compliance between
ELAMEFELAM
syad563-0syad563-0
No. at Risk1 1311311
31901stnevEfo.oN
No. Censored2 37305
Kaplan-Meier Estimate3 658.0588.0
640.0310.0rorrEdradnatSoteP
1 Number of subjects at risk at the beginning of interval. 
2 Subjects are censored because no event was observed by the end of time interval, including those not yet reached the 
end of the time interval or lost to follow-up. 
3 Estimate made at end of time interval. 
Number at risk 
Days  0 30       365 
Male  1131 1060       538 
Female  131 121       45 
Fig 1. One-year Kaplan-Meier estimates for major adverse events (MAE) by gender.
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presence of a stent graft, perhaps having less degeneration
over time. Ouriel et al documented more rapid sac
shrinkage among women treated with EVAR.17 Egorova
et al found that the early discrepancy in outcomes after
an EVAR between men and women equalized 2 years after
treatment, again suggesting that some aspects of female
anatomy may translate into superior durability over the
long term.20 Our early results cannot address this question,
but the procedural differences we identiﬁed do suggest
women had fewer aneurysmal iliac arteries among the
ENGAGE cohort.
One of the most concerning observations in the liter-
ature is the increased mortality associated with EVAR in
women.3,16,23 It is not entirely clear why women tend to
have a higher mortality than men when undergoing AAA
repair.3,16 McPhee et al, in a study using National Inpa-
tient Sample data, found female gender to be an indepen-
dent risk factor for mortality after both open andendovascular aneurysm repair, even after controlling for
differences in age and comorbidities.16 Similarly, Mehta
et al, in a single-center case series, found women to be
3.4 times more likely than men to die after an EVAR.3
They identiﬁed some key differences between men and
women that partially explain the discrepancy in mortality.
Women were more likely to suffer intraoperative arterial
rupture than men (4% vs 1.2%), mainly because of more
hostile aortic neck and iliac anatomy; and women were
more likely to have access-related complications.3 Abedi
et al, using the American College of Surgeons National
Surgical Quality Improvement Program database, found
women to be at higher risk of death after an EVAR.23
They attributed this higher risk in part to a higher
proportion of emergent operations, greater physical
debilitation, and a greater need for iliac or brachial expo-
sure in women.
Among the ENGAGE cohort, no difference in in-
hospital or 30-day mortality was observed between men
ELAMEFELAM
syad563-0syad563-0
No. at Risk1 1311311
0117stnevEfo.oN
No. Censored2 37025
Kaplan-Meier Estimate3 488.029.0
240.0110.0rorrEdradnatSoteP
1 Number of subjects at risk at the beginning of interval. 
2 Subjects are censored because no event was observed by the end of time interval, including those not yet reached the 
end of the time interval or lost to follow-up. 
3 Estimate made at end of time interval. 
Number at risk: 
Days:  0 30        365 
Male  1131 1088        559 
Female  131 123        48 
Fig 2. One-year Kaplan-Meier estimates for all-cause mortality by gender.
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similar rates of comorbidities with the exception of a lower
rate of coronary artery disease. Women are known to be
more likely to present emergently with aneurysms.3,16,23
Although the present series was limited to aneurysms
treated electively, we did identify a higher proportion of
symptomatic aneurysms among women. This did not,
however, translate into worse outcomes among women.
Most baseline differences between men and women
were similar, although women were more likely than
men to have a family history of aneurysms (10.7% vs
6.1%; P ¼ .04). Familial aneurysms are more common
among women.24 This may reﬂect a greater role of genetic
susceptibility in the pathogenesis of female aneurysm
formation.
The ENGAGE Registry provides information on the
real-life experience with the Endurant stent graft. All
patients reported here had to meet the speciﬁc inclusioncriteria of the ENGAGE Registry, which included suit-
ability for EVAR, thus representing some selection bias.
Women represented a much smaller proportion of patients
treated than men, although they were similar in terms of
baseline differences. Although mortality was similar at
1 year, our endovascular-speciﬁc outcomes (endoleaks)
were limited to 30 days after implantation. Further study
is needed to ensure long-term outcomes remain similar
for both genders. The results from the multinational
ENGAGE Registry are similar to those reported for the
Endurant device in other reports, including that of a recent
Canadian multicenter registry.25
This study has several limitations. Although it includes
a large number of patients, the ENGAGE Registry was not
prospectively powered to assess differences between
genders, nor does it represent a matched comparison. In
addition, outcomes were reported by the treating surgeons,
which may represent some bias. Any comparison with
JOURNAL OF VASCULAR SURGERY
Volume 57, Number 2 Dubois et al 389historical controls, or previous reports, is difﬁcult, as the
inﬂuence of the Endurant stent graft is difﬁcult to separate
from such advances as improvements in imaging and
increased operator experience. Also, this report represents
short-term outcomes, some of which differed between
sexes, but did not reach statistical signiﬁcance, possibly rep-
resenting a type II error. Long-term outcomes are neces-
sary to further clarify many of these issues.
This study’s results are supported by prospective,
systematic data collection and the inclusion of multi-
center/multinational patients. We have shown that despite
clear anatomic differences between men and women, early
results using the Endurant graft are similar for the genders,
with equivalent mortality, freedom from secondary endo-
vascular procedures, freedom from major adverse events,
and freedom from type I/III endoleaks. As with all
EVAR series, long-term follow-up will determine whether
these outcomes remain durable.AUTHOR CONTRIBUTIONS
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